Long non‑coding RNA AFAP1‑antisense RNA 1 promotes the proliferation, migration and invasion of gastric cancer cells and is associated with poor patient survival

  • Authors:
    • Huazhou Zhao
    • Kecheng Zhang
    • Ting Wang
    • Jianxin Cui
    • Hongqing Xi
    • Yi Wang
    • Yanjing Song
    • Xudong Zhao
    • Bo Wei
    • Lin Chen
  • View Affiliations

  • Published online on: March 30, 2018     https://doi.org/10.3892/ol.2018.8389
  • Pages: 8620-8626
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer (GC) is the second‑leading cause of cancer‑associated mortality worldwide. AFAP1‑antisense RNA 1 (AFAP1‑AS1), a long non‑coding RNA (lncRNA), is believed to promote the aggressive progression of cancer; however, its role in GC remains largely unknown. In the present study, the expression of AFAP1‑AS1 in GC tissues and cell lines was measured using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Knockdown of AFAP1‑AS1 was performed using a lentiviral vector containing a short hairpin RNA. The proliferation of GC cells was measured using Cell Counting kit‑8. The migration and invasion of GC cells were analyzed using a QCM Laminin Migration Assay kit and a Cell Invasion Assay kit. The levels of epithelial‑mesenchymal transition (EMT)‑associated proteins were detected by western blot analysis. The cut‑off value of the expression of AFAP1‑AS1 was evaluated using receiver operating characteristic (ROC) curves and patient survival rate was analyzed using Kaplan‑Meier. The expression of AFAP1‑AS1 was significantly increased in the primary tumor tissues of GC patients with lymph node metastasis or tumor node metastasis stage (stage III or IV; P<0.01). ROC curve analysis revealed that the expression of AFAP‑AS1, at a cut‑off value of 0.5040, could distinguish GC tissues from the matched normal tissues, with an AUC of 0.8802, sensitivity of 81.25% and specificity of 83.75%. The overexpression of AFAP1‑AS1 was positively associated with the poor survival rates of GC patients. Furthermore, the downregulation of AFAP1‑AS1 significantly inhibited the proliferation, migration and invasion of GC cells in vitro (P<0.01). The decrease in AFAP1‑AS1 expression significantly suppressed the expression level of N‑cadherin protein in GC cells and increased that of E‑cadherin. The present study demonstrated that the expression signature of AFAP1‑AS1 may serve as a biomarker for the diagnosis and prognosis of GC, and its downregulation may repress the aggressive progression of GC, partially through inhibiting the EMT progress.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao H, Zhang K, Wang T, Cui J, Xi H, Wang Y, Song Y, Zhao X, Wei B, Chen L, Chen L, et al: Long non‑coding RNA AFAP1‑antisense RNA 1 promotes the proliferation, migration and invasion of gastric cancer cells and is associated with poor patient survival. Oncol Lett 15: 8620-8626, 2018
APA
Zhao, H., Zhang, K., Wang, T., Cui, J., Xi, H., Wang, Y. ... Chen, L. (2018). Long non‑coding RNA AFAP1‑antisense RNA 1 promotes the proliferation, migration and invasion of gastric cancer cells and is associated with poor patient survival. Oncology Letters, 15, 8620-8626. https://doi.org/10.3892/ol.2018.8389
MLA
Zhao, H., Zhang, K., Wang, T., Cui, J., Xi, H., Wang, Y., Song, Y., Zhao, X., Wei, B., Chen, L."Long non‑coding RNA AFAP1‑antisense RNA 1 promotes the proliferation, migration and invasion of gastric cancer cells and is associated with poor patient survival". Oncology Letters 15.6 (2018): 8620-8626.
Chicago
Zhao, H., Zhang, K., Wang, T., Cui, J., Xi, H., Wang, Y., Song, Y., Zhao, X., Wei, B., Chen, L."Long non‑coding RNA AFAP1‑antisense RNA 1 promotes the proliferation, migration and invasion of gastric cancer cells and is associated with poor patient survival". Oncology Letters 15, no. 6 (2018): 8620-8626. https://doi.org/10.3892/ol.2018.8389